Stablix
Uddhav is passionate about drugging the undruggable. He has managed and established teams and laboratory capabilities for chemical synthesis, protein bioscience, protein complex crystallography, biochemical and biophysical assays as a founding scientist in three biotech startups. Notably, he designed first generation compounds for KRAS(G12C)-Cyclophilin A “Tri-Complex” inhibitors at WarpDrive Bio, currently the only compounds in clinical development that inhibit the active form of KRAS(G12C).
This person is not in any offices
Stablix
Stablix is pioneering an entirely new field of targeted protein stabilization (TPS) to bring transformative medicines to patients with unmet medical need.